Stryker Corp. filed a Form 8-K on June 26, 2026, to report changes to its segment reporting following an organizational restructuring announced in the first quarter of 2026. The filing does not report a merger, financing, securities issuance, insider transaction, or change in control. Instead, it updates how the company presents historical financial information to align with its revised business structure. The Kalamazoo, Michigan-based medical technology company said it created a new “Ortho Tech” business that combines the orthopaedic instruments portfolio from its Instruments business with the Mako and enabling technologies portfolio from its Other Orthopaedics business. Stryker said the move brings together Mako, power tools, cutting accessories, enabling technologies, and related teams under one business, with the goal of simplifying the customer experience and increasing speed to market through more focused innovation. Despite the internal reorganization, Stryker will continue to report two business segments: MedSurg and Neurotechnology, and Orthopaedics. Each will remain a reportable segment. The key accounting effect is that prior-period financial statement presentation must be recast to reflect the updated segment structure when incorporated into future registration statements, proxy statements, or information statements. To address that requirement, Stryker filed recast consolidated financial statements covering each of the three years in the period ended December 31, 2025. The company emphasized that the updates are not a restatement of previously issued audited financial statements and do not amend the underlying financial results reported in its 2025 Annual Report. Rather, the changes are intended to present historical results under the new segment reporting framework. The filing was made under Item 8.01, “Other Events,” and Item 9.01, “Financial Statements and Exhibits.” Exhibit 99.1 contains the recast portions of Stryker’s Annual Report on Form 10-K for the year ended December 31, 2025, while Exhibit 23.1 provides the consent of the company’s independent registered public accounting firm. Stryker also included standard inline XBRL exhibits related to the filing. Stryker cautioned that the 8-K is presented for informational purposes only in connection with the segment reporting changes. It does not update management’s discussion and analysis or reflect developments after the filing of the 2025 Annual Report, except for the segment-related recast. The company pointed investors to its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, and other more recent filings for current information about subsequent events, risks, expectations, and developments. The report was signed by Preston W. Wells, Vice President and Chief Financial Officer, on June 26, 2026.